Inflammatory Biomarkers and Mortality Risk among HIV-Suppressed Men: A Multisite Prospective Cohort Study

Clinical Infectious Diseases

Volumn 63, Issue 7, 2016, Pages 984-990

  Wada, Nikolas I ^a   Bream, Jay H ^a   Martínez Maza, Otoniel ^b   Macatangay, Bernard ^c   Galvin, Shannon R ^d   Margolick, Joseph B ^a   Jacobson, Lisa P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

biomarkers; cART; HIV; inflammation; mortality

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CXCL13 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOKINE;

ADULT; AGE; ARTICLE; CALIFORNIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; EXPLORATORY FACTOR ANALYSIS; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLINOIS; MAJOR CLINICAL STUDY; MALE; MARYLAND; MEN WHO HAVE SEX WITH MEN; MORTALITY RISK; MULTICENTER STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; BIOMARKERS; CD4 LYMPHOCYTE COUNT; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84990914052     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw409     Document Type: Article

References (29)

1. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS 2014; 28:257-65.
2. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-18.
3. Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
4. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and the risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-6.
5. Wada N, Jacobson L, Cohen M, French AL, Phair JP, Muñoz A. Cause-specific life expectancies after age 35 for HIV-infected and HIV-negative individuals followed simultaneously in long-term cohort studies: 1984-2008. Am J Epidemiol 2013; 177:116-25.
6. Achenbach CJ, Buchanan AL, Cole SR, et al. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis 2014; 58:1599-606.
7. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119:51-83.
8. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
9. French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 2009; 200:1212-5.
10. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29:463-71.
11. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2595-9.
12. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106:506-12.
13. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-805.
14. Ledwaba L, Tavel JA, Khabo P, et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012; 7:e24243.
15. Sandler NG,Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
16. Andrade BB, Hullsiek KH, Boulware DR, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 2013; 207:1379-88.
17. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
18. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-22.
19. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228-38.
20. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, Ddimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-46.
21. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
22. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-8.
23. Hultin LE, Menendez FA, Hultin PM, et al. Assessing immunophenotyping performance: proficiency-validation for adopting improved flow cytometry methods. Cytometry B Clin Cytom 2007; 72:249-55.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57:289-300.
25. Visconti L, Nelissen K, Deckx L, et al. Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients. Biomark Med 2014; 8:297-306.
26. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144:480-4.
27. Shive CL, Biancotto A, Funderburg NT, et al. HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr 2012; 61:145-52.
28. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22:347-52.
29. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992; 127:25-50.